http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 07 Oct 2026 07:26:53 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/New+Coverage/Deutsche+Bank+Starts+Stevanato+Group+S.p.A.+%28STVN%29+at+Hold/27157967.html <p>Deutsche Bank analyst Justin Bowers initiates coverage on Stevanato Group S.p.A. (NYSE: STVN) with a Hold rating and a price target of $22.00.</p> <p>For an analyst ratings summary and ratings history on Stevanato Group S.p.A. <a href="http://www.streetinsider.com/rating_history.php?q=STVN">click here</a>. For more ratings news on Stevanato Group S.p.A. <a href="http://www.streetinsider.com/stock_lookup_news.php?q=STVN&amp;type=analyst">click here</a>.</p> <p>Shares of Stevanato Group S.p.A. closed at $19.86 yesterday.</p> http://www.streetinsider.com/New+Coverage/Deutsche+Bank+Starts+Stevanato+Group+S.p.A.+%28STVN%29+at+Hold/27157967.html Wed, 07 Oct 2026 07:26:53 -0400 STVN http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Stevanato+Group+S.p.A.++++For%3A+Sep+28++Filed+by%3A+Stocchi+Mauro/27129593.html si-local-file:///var/storage/secattach/20260930/27129593.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Stevanato+Group+S.p.A.++++For%3A+Sep+28++Filed+by%3A+Stocchi+Mauro/27129593.html Wed, 30 Sep 2026 17:21:00 -0400 STVN http://www.streetinsider.com/SEC+Filings/Form++144++++++++Stevanato+Group+S.p.A.+++++++++++++++++Filed+by%3A+Stocchi+Mauro/27056613.html si-local-file:///var/storage/secattach/20260914/27056613.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Stevanato+Group+S.p.A.+++++++++++++++++Filed+by%3A+Stocchi+Mauro/27056613.html Mon, 14 Sep 2026 09:58:00 -0400 STVN http://www.streetinsider.com/New+Coverage/UBS+Assumes+Stevanato+Group+S.p.A.+%28STVN%29+at+Neutral/27038784.html <p>UBS analyst Douglas Schenkel assumes coverage on Stevanato Group S.p.A. (NYSE: STVN) with a Neutral rating.</p> <p>For an analyst ratings summary and ratings history on Stevanato Group S.p.A. <a href="http://www.streetinsider.com/rating_history.php?q=STVN">click here</a>. For more ratings news on Stevanato Group S.p.A. <a href="http://www.streetinsider.com/stock_lookup_news.php?q=STVN&amp;type=analyst">click here</a>.</p> <p>Shares of Stevanato Group S.p.A. closed at $20.32 yesterday.</p> http://www.streetinsider.com/New+Coverage/UBS+Assumes+Stevanato+Group+S.p.A.+%28STVN%29+at+Neutral/27038784.html Wed, 09 Sep 2026 06:08:22 -0400 STVN http://www.streetinsider.com/Press+Releases/Stevanato+Group+to+Participate+in+Two+Upcoming+Investor+Conferences/27036591.html <p> PIOMBINO DESE, Italy--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.stevanatogroup.com%2Fen%2F&amp;esheet=54600434&amp;newsitemid=20260908397502&amp;lan=en-US&amp;anchor=Stevanato+Group+S.p.A.&amp;index=1&amp;md5=e2aabfaea2c048fb03af683352a8246f" shape="rect">Stevanato Group S.p.A.</a> (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences: </p><ul class="bwlistdisc"> <li> Tuesday, September 15, at 1:50 p.m. (ET) – Morgan Stanley Annual Global Healthcare Conference, New York, NY </li> <li> Tuesday, September 22, at 8:25 – 9:05 a.m. (GMT) – BofA Global Healthcare Conference, London, UK </li> </ul><p> A live webcast for each event will be available on the Company’s website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.stevanatogroup.com%2F&amp;esheet=54600434&amp;newsitemid=20260908397502&amp;lan=en-US&amp;anchor=www.stevanatogroup.com&amp;index=2&amp;md5=48c8b02f84bc4e584c809dfc58a70fe7" shape="rect">www.stevanatogroup.com</a> under the "Investors" http://www.streetinsider.com/Press+Releases/Stevanato+Group+to+Participate+in+Two+Upcoming+Investor+Conferences/27036591.html Tue, 08 Sep 2026 16:05:00 -0400 STVN http://www.streetinsider.com/Business+Wire/Stevanato+Group+to+Participate+in+Two+Upcoming+Investor+Conferences/27036591.html <p> PIOMBINO DESE, Italy--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.stevanatogroup.com%2Fen%2F&amp;esheet=54600434&amp;newsitemid=20260908397502&amp;lan=en-US&amp;anchor=Stevanato+Group+S.p.A.&amp;index=1&amp;md5=e2aabfaea2c048fb03af683352a8246f" shape="rect">Stevanato Group S.p.A.</a> (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences: </p><ul class="bwlistdisc"> <li> Tuesday, September 15, at 1:50 p.m. (ET) – Morgan Stanley Annual Global Healthcare Conference, New York, NY </li> <li> Tuesday, September 22, at 8:25 – 9:05 a.m. (GMT) – BofA Global Healthcare Conference, London, UK </li> </ul><p> A live webcast for each event will be available on the Company’s website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.stevanatogroup.com%2F&amp;esheet=54600434&amp;newsitemid=20260908397502&amp;lan=en-US&amp;anchor=www.stevanatogroup.com&amp;index=2&amp;md5=48c8b02f84bc4e584c809dfc58a70fe7" shape="rect">www.stevanatogroup.com</a> under the "Investors" http://www.streetinsider.com/Business+Wire/Stevanato+Group+to+Participate+in+Two+Upcoming+Investor+Conferences/27036591.html Tue, 08 Sep 2026 16:05:00 -0400 STVN http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Stevanato+Group+S.p.A.+++++++++++++++++Filed+by%3A+T.+Rowe+Price+Investment+Management%2C+Inc./26926662.html si-local-file:///var/storage/secattach/20260814/26926662.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Stevanato+Group+S.p.A.+++++++++++++++++Filed+by%3A+T.+Rowe+Price+Investment+Management%2C+Inc./26926662.html Fri, 14 Aug 2026 10:40:00 -0400 O.00531653 STVN http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Stevanato+Group+S.p.A.+++++++++++++++++Filed+by%3A+T.+Rowe+Price+Investment+Management%2C+Inc./26926662.html si-local-file:///var/storage/secattach/20260814/26926662.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Stevanato+Group+S.p.A.+++++++++++++++++Filed+by%3A+T.+Rowe+Price+Investment+Management%2C+Inc./26926662.html Fri, 14 Aug 2026 10:40:00 -0400 O.00531653 STVN http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Stevanato+Group+S.p.A.+++++++++++++++++Filed+by%3A+Artisan+Partners+Limited+Partnership/26921837.html si-local-file:///var/storage/secattach/20260813/26921837.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Stevanato+Group+S.p.A.+++++++++++++++++Filed+by%3A+Artisan+Partners+Limited+Partnership/26921837.html Thu, 13 Aug 2026 16:31:00 -0400 O.00531653 STVN http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Stevanato+Group+S.p.A.+++++++++++++++++Filed+by%3A+Artisan+Partners+Limited+Partnership/26921837.html si-local-file:///var/storage/secattach/20260813/26921837.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Stevanato+Group+S.p.A.+++++++++++++++++Filed+by%3A+Artisan+Partners+Limited+Partnership/26921837.html Thu, 13 Aug 2026 16:31:00 -0400 O.00531653 STVN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Stevanato+Group+S.p.A.++++For%3A+Aug+07++Filed+by%3A+Dal+Lago+Marco/26898105.html si-local-file:///var/storage/secattach/20260810/26898105.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Stevanato+Group+S.p.A.++++For%3A+Aug+07++Filed+by%3A+Dal+Lago+Marco/26898105.html Mon, 10 Aug 2026 16:15:00 -0400 O.00531653 STVN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Stevanato+Group+S.p.A.++++For%3A+Aug+07++Filed+by%3A+Dal+Lago+Marco/26898105.html si-local-file:///var/storage/secattach/20260810/26898105.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Stevanato+Group+S.p.A.++++For%3A+Aug+07++Filed+by%3A+Dal+Lago+Marco/26898105.html Mon, 10 Aug 2026 16:15:00 -0400 O.00531653 STVN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Stevanato+Group+S.p.A.++++For%3A+Aug+07++Filed+by%3A+Magistretti+Elisabetta/26898106.html si-local-file:///var/storage/secattach/20260810/26898106.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Stevanato+Group+S.p.A.++++For%3A+Aug+07++Filed+by%3A+Magistretti+Elisabetta/26898106.html Mon, 10 Aug 2026 16:15:00 -0400 O.00531653 STVN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Stevanato+Group+S.p.A.++++For%3A+Aug+07++Filed+by%3A+Magistretti+Elisabetta/26898106.html si-local-file:///var/storage/secattach/20260810/26898106.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Stevanato+Group+S.p.A.++++For%3A+Aug+07++Filed+by%3A+Magistretti+Elisabetta/26898106.html Mon, 10 Aug 2026 16:15:00 -0400 O.00531653 STVN